November 4, 2025
In the fall of 2025, direct-to-consumer (DTC) prescription drug websites, launched by pharmaceutical manufacturers, began reshaping how Americans access their medications. These platforms promise lower prices by selling directly to patients—typically at a cash price and outside the traditional insurance channels. While the concept isn’t entirely new, the rapid expansion of DTC sites signal a shift in how drug pricing is being approached in the U.S.
Eli Lilly was among the early adopters, introducing its Lilly Direct platform back in January 2024. Through the platform, patients could purchase medications like Zepbound at reduced cash prices. The DTC model has gained momentum not only as an innovative business strategy, but also as a response to federal pricing initiatives—particularly the Most Favored Nation (MFN) pricing plan, which aims to align U.S. drug prices with those in other developed countries.
One of the most notable developments in this space is the announcement of TrumpRx, a government-backed website designed to aggregate DTC drug offerings from major manufacturers. Its goal is to improve access to discounted medications for Americans. Pfizer, Amgen and AstraZeneca were among the first to sign on. Rather than selling drugs directly, TrumpRx acts as a portal, directing patients to manufacturer sites where they can complete their purchases.
Are Direct-to-Consumer Prescription Drugs Cheaper?
On the surface, DTC pricing seem like a win for consumers. Unlike traditional brand-name prescriptions, which often come with a high list price followed by rebates months later, DTC drugs are sold at a lower upfront cost with no rebate mechanism. This transparency can be appealing, especially for patients paying out of pocket. However, the math isn’t always in the patient’s favor. For example, Xeljanz was announced with a 40% discount once TrumpRx goes live in 2026. However, rebate data at the time showed that traditional insurance channels would secure rebates in the 45–55% range. This illustrates that while the DTC model eliminates the wait and complexity of rebates, it doesn’t always result in a lower net cost.
What are the Types of DTC Drugs Being Offered?
DTC platforms add complexity not just in pricing, but also in which drugs are offered. While some high-demand medications like Lilly’s GLP-1 weight loss drug are included, many others are niche or face heavy competition. Afrezza, a rarely prescribed inhaled insulin, is one such example. Zavzpret, a newer migraine treatment, was also added to TrumpRx despite lagging behind its peers in market uptake. Cosentyx, though lacking a direct biosimilar, competes in a crowded therapeutic space where biosimilar-first strategies are gaining ground. Farxiga, a widely used diabetes medication, is already available as an authorized generic—and with 18 generic manufacturers expected to enter the market in 2026, its inclusion on TrumpRx may have limited impact on overall affordability.
How do DTC Drugs Impact Employer-Sponsored Health Plans?
For patients with employer-sponsored health plans, the DTC model presents both opportunities and challenges. Most DTC platforms don’t accept insurance, requiring patients to pay the full cash price. While this may work for inexpensive generics, brand-name drugs can remain prohibitively expensive. For example, Cosentyx, even at a 55% discount, still costs around $3,600 per month—a recurring expense that few can afford without assistance. Some vendors are exploring ways to help employers subsidize these costs for their members, but introducing new intermediaries could increase complexity and administrative expenses.
What Are the Pros and Cons of DTC Prescription Drugs?
DTC prescription platforms present both opportunities and challenges for consumers and plan sponsors, including:
Pros:
- Transparent pricing
- Potential cost savings
- Consumer empowerment
- Convenience
- Accessibility
Cons:
- Added complexity
- Limited range of drugs
- Insurance is usually not accepted
- Potential for higher costs
Conclusion
Ultimately, while DTC websites represent a promising step toward pricing transparency and consumer empowerment, their long-term impact remains uncertain. Will they truly lower costs for patients and employers or simply shift the burden in new ways? As more manufacturers and policymakers join the conversation, the answers may become clearer—but for now, the DTC movement is one to watch closely.
